LINEDA CERESTE: Open Payments
NPI 1982388575 · MAITLAND, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,346 in 51 payments from 14 companies in 2025. Trend: 2023 $146 · 2024 $140 · 2025 $1,346
Food & beverage: $1,346
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $414 |
| Neurocrine BioSciences, Inc. | 16 | $321 |
| Otsuka America Pharmaceutical, Inc. | 6 | $209 |
| Janssen Pharmaceuticals, Inc | 4 | $91 |
| Lundbeck LLC | 3 | $75 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
Products named: VRAYLAR, INGREZZA, REXULTI, ABILIFY MAINTENA, INVEGA SUSTENNA, CAPLYTA, Auvelity, Qelbree.
Industry payments across FL — which companies pay providers there.
